Sikander Ailawadhi

Jacksonville College — United States

Medicine · Health Sciences

42h-index7.0kcitations703works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(335), Chronic Lymphocytic Leukemia Research(205), Protein Degradation and Inhibitors(128), Chronic Myeloid Leukemia Treatments(75), Lymphoma Diagnosis and Treatment(73)

Publications703 total

Quantitative bias analyses to address measurement error in time-to-event endpoints
American Journal of Epidemiology·2026Open Access
Investigating the Role of Dexamethasone Prophylaxis for the Risk Reduction of Immune Effector Cell Delayed Neurotoxicity in Cilta-Cel Treated Patients
Transplantation and Cellular Therapy·2026
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)
Expert Review of Hematology·2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia
Blood Advances·2026Open Access
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma
Blood Cancer Journal·2025Open Access
Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia
Haematologica·2025Open Access
A plain language summary of patient preferences for treatments for multiple myeloma that has relapsed or is refractory to prior therapy
Future Oncology·2025Open Access
Supplementary Figure 4 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 3 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Data 1 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 2 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 1 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 7 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 5 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figure 6 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2025Open Access
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2025Open Access
Supplementary Figure 8 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
2025Open Access
Supplementary Figure 9 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
2025Open Access
page 1 of 36Next →

Frequent Co-authors

Asher Chanan‐Khan(21), Vivek Roy(13), Taimur Sher(13), Shaji Kumar(12), Angela Dispenzieri(11), Yi Lin(11), S. Vincent Rajkumar(11), Martha Q. Lacy(10), David Dingli(10), Francis K. Buadi(10), Morie A. Gertz(10), Craig B. Reeder(10), Prashant Kapoor(10), P. Leif Bergsagel(9), Ronald S. Go(9), Aneel Paulus(9), Wilson I. Gonsalves(8), Nelson Leung(8), Rafaël Fonseca(7), Robert A. Kyle(7)